drugset / Trial / NCT04032704
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.
Timeline
- Start
- 2019-10-09
- Primary completion
- 2023-11-28
- Completion
- 2023-11-28
Outcome
Outcome not reported
Stopped (Business): “Study closed due to portfolio prioritization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | ladiratuzumab vedotin | Unknown | — | Intravenous |